Abstract
Introduction
Percutaneous coronary intervention (PCI) has revolutionized the management and outcomes of patients with ST-segment elevation myocardial infarction (STEMI) [1] . Primary PCI, according to the European Society of Cardiology (ESC) 2008 guidelines, is the treatment of choice in patients with STEMI within 12 h of chest pain onset [2] . However, the time delay associated with transportation to a hospital with a catheterization laboratory is a major drawback of primary PCI and may have an adverse effect on outcomes [3] . Diabetes mellitus (DM) is associated with a greater extent of myocardial ischemia and increased mortality after STEMI [4, 5] . The presence of normal thromb olysis in myocardial infarction (TIMI) fl ow grade 3 in the infarct-related artery (IRA) before PCI improves left ventricular function, lowers incidence of congestive heart failure, and decreases mortality compared to patients without initial TIMI fl ow grade 3 [6, 7] . Yet, its incidence and impact among diabetic patients are unclear. Patients with DM have impaired endogenous fi brinolytic activity [8] . Therefore, the rate of spontaneous reperfusion (SR) before PCI may be altered and may have an adverse effect on outcomes.
The aim of this study was to evaluate the association of DM with the rate of SR before PCI and its effect on the immediate and long-term outcomes. This is an analysis of patients with STEMI and multivessel coronary artery disease (CAD), who are in our database (unpublished data).
Methods
A total of 1,850 patients with STEMI and multivessel CAD undergoing primary PCI were enrolled and divided into 4 groups depending on their DM status and initial TIMI fl ow in the IRA: -Group 1 -patients with DM and initial TIMI < 3 fl ow (n = 491); -Group 2 -patients with DM and initial TIMI 3 fl ow (n = 48); -Group 3 -patients without DM and with initial TIMI < 3 fl ow (n = 1,196); -Group 4 -patients without DM and with initial TIMI 3 fl ow (n = 115). SR before PCI was defi ned as the presence of TIMI 3 fl ow in the IRA. Multivessel CAD was defi ned as the presence of at least 70% stenosis of at least 2 epicardial coronary arteries. DM was defi ned as: (a) preexisting condition diagnosed before STEMI (patients on insulin, oral glucose-lowering drugs or on a diet), (b) newly diagnosed DM based on fasting plasma glucose (FPG) ≥ 7.0 mmol/L or 2-h plasma glucose ≥ 11.1 mmol/L during an oral glucose tolerance test (OGTT) [9] . To avoid acute hyperglycemia, FPG was taken into consideration after the third day of hospital stay. For that reason, OGTT was performed on day 4 of hospital stay or later. The defi nition of STEMI was as follows: 1) ST-segment elevation consistent with MI of at least 2 mm in contiguous precordial leads and/or ST-segment elevation of at least 1 mm in 2 or more limb leads or new left bundle branch block, and 2) positive cardiac necrosis markers (CK-MB and/or troponin). Patients received 300 mg of acetylsalicylic acid (ASA) loading dose and 600 mg of clopidogrel loading dose, followed by 75 mg of ASA maintenance dose and 75 mg of clopidogrel maintenance dose [10] . Coronary angiography and PCI were performed using standard protocols and guidelines. A culprit lesion was described in the presence of an acute occlusion, intraluminal fi lling defects (or thrombus), ulcerated plaques, dissection, or intraluminal fl aps. The baseline and post-procedural blood flow in the IRA was quantifi ed with the TIMI grading system [11] . Angiographic measurements were made using quantitative coronary angiography and the automated coronary analysis system (CDM 3500 View Station, Philips Medical Systems, Leiden, The Netherlands). All patients received bare-metal stents. Successful PCI was defi ned as a post-procedural residual-diameter stenosis < 30%, with TIMI 3 fl ow in the IRA and no procedural complications.
All patients were scheduled for an elective 1-year clinical follow-up. We clinically monitored the patients for cardiovascular events. The major adverse cardiac and cerebrovascular events included death, rehospitalization for acute coronary syndromes (STEMI, non-STEMI, unstable angina), and stroke.
Approval for analyzing recorded data was waived by the local bioethics committee on human research given the retrospective nature of the study.
Statistical analysis
Quantitative data are presented as means ± ± standard deviations (SD) or medians with interquartile ranges (lower and upper quartiles). Qualitative data are presented as frequencies. The Shapiro-Wilk test was used to determine whether random samples came from a normal distribution. -Meier method and compared with the log-rank test. All clinical variables and laboratory fi ndings with a p value £ 0.2 in the univariate analysis were entered into the multivariate logistic regression model using a Wald statistic backward stepwise selection. Multivariate logistic regression analysis was performed to estimate odds ratios (OR) and 95% confi dence intervals (95% CI) to identify independent predictors of baseline and fi nal TIMI 3 fl ow. The Cox proportional hazard survival model was used to assess the association between TIMI fl ow grade and 1-year mortality while adjusting for potential confounders. A value of p < 0.05 was considered signifi cant.
Results
A total of 539 diabetic patients entered the study, of whom 48 (8.9%) had SR before PCI. Additionally, 1,311 non-diabetic patients were enrolled, of whom 115 (8.8%) had SR before PCI (p = 0.8). Baseline and clinical characteristics are presented in Table 1 . Diabetic patients (irrespective of initial TIMI fl ow) were older and more frequently female. The time from symptoms onset was substantially longer in diabetic patients with no SR before PCI. The duration of chest pain was similar in the other 3 groups. Angiographic parameters were similar (Table 2 ) except for the rate of fi nal TIMI 3 fl ow, Andrzej Lekston et al., Spontaneous coronary reperfusion and diabetes mellitus which was higher in patients with SR (irrespective of their diabetes status). Laboratory fi ndings are given in Table 3 . Peak creatine phosphokinase was higher in diabetic and non-diabetic patients with initial TIMI 0-2 flow (group 1 and group 3). In-hospital mortality rate was the highest in group 1 and the lowest in group 4 (p < 0.0001). Meanwhile, the death rates of patients from groups 2 and 3 were similar (approximately 8.3% each, p = 0.9). Multivariate logistic regression revealed that only cardiogenic shock on admission (OR 0.25, 95% CI 0.10-0.63, p = 0.003) and time from symptoms onset (OR 0.95, 95% CI 0.90-0.99, p = 0.03) independently decreased the chance of SR before PCI. Independent predictors of final TIMI 3 flow are depicted in Figure 1 . Cardiogenic shock, DM, older age, time from symptoms onset, ejection fraction, and final TIMI 3 flow independently predicted in-hospital mortality (Fig. 2) . Non-diabetic patients had a higher 1-year survival rate than diabetic patients, irrespective of their initial TIMI flow (Fig. 3) . The Cox proportional hazard survival model showed that only DM, cardiogenic shock, and older age were independently associated with 1-year mortality, whereas higher ejection fraction and final TIMI 3 flow decreased the risk of death in long-term follow-up (Fig. 4) .
Discussion
The results of our study indicate that the rate of SR before PCI was similar in diabetic and non--diabetic patients (8.9% vs. 8.8%). Of note, diabetic patients with no SR had substantially longer time from symptoms onset than diabetic patients with SR and all non-diabetic patients. Multivariate logistic regression revealed that only cardiogenic shock and the time from symptoms onset were independent predictors of SR before PCI. The presence of initial TIMI 3 fl ow was associated with successful PCI both in diabetic and non-diabetic patients. Our study documents superior outcomes in patients who achieve TIMI 3 fl ow before intervention. In--hospital mortality was the highest in diabetic patients with no SR, intermediate in diabetic patients with SR and non-diabetic patients with no SR, and the lowest in non-diabetic patients with SR. Non--diabetic patients, irrespective of their reperfusion on admission status, had a good 1-year survival rate. Diabetic patients (irrespective of their reperfusion on admission status) had a worse survival rate than non-diabetics. Post-procedural success (fi nal TIMI 3 fl ow) but not SR (initial TIMI 3 fl ow) was an independent predictor of 1-year mortality.
Diabetic and non-diabetic patients with initial TIMI 3 fl ow also had higher procedural success and smaller infarct sizes (lower peak creatine kinase values). Despite smaller infarct size and lower procedural success, a greater preservation of left ventricular function was observed only in non-diabetic patients.
Unfavorable course of STEMI in diabetic patients may be associated with endothelial dysfunction, promoting vasoconstriction; infl ammation and hypercoagulability [12] [13] [14] ; increased platelet aggregation, leading to thrombosis [15, 16] ; and impaired endogenous fi brinolytic activity [8, 17] . The rate of SR in our study was similar to that observed in other studies [18] [19] [20] . Unlike other studies, our reports similar frequencies of SR in diabetic and non-diabetic patients. The benefi t of SR before intervention is due to multiple factors and has been studied in a few reports. Gustafson et al. [21] reported that patients with initial TIMI 2 or 3 fl ow had lower mortality (1.7% vs. 4.3%, p = 0.02) and a higher acute ejection fraction (49.5% vs. 47.1%, p = 0.002). Brodie et al. [22] presented similar results. Interestingly, they both observed a better ejection fraction in patients with patent IRA on initial angiography. In our study, we observed no association between initial TIMI fl ow and ejection fraction. However, we did observe that diabetic patients (irrespective of their SR status) had more depressed left ventricular contractile function. Stone et al. [6] , in an analysis of 2,507 patients from four major PAMI trials, found that initial TIMI 3 fl ow was a powerful and independent predictor of in-hospital and late survival. We observed a similar trend in our study; nevertheless, SR on admission was not independently correlated with in-hospital and late survival. Only fi nal TIMI 3 fl ow was an independent predictor of better survival. Supporting the role of pre-procedural IRA patency, De Luca et al. [24] found initial TIMI fl ow to be independently associated with 1-year mortality in high-risk patients (according to TIMI risk score [23] ), but not in low-risk patients. There is only 1 prior report on the association of initial TIMI fl ow and DM. Bainey et al. [25] analyzed 4,944 patients (15.5% diabetic) undergoing primary PCI in the APEX AMI study. They reported that patients with SR had improved post-PCI TIMI 3 fl ow compared to those without SR in non--diabetic patients (99.8% vs. 90.3%, p < 0.001) and in diabetic patients (98.6% vs. 84.9%, p < 0.001). They also observed that non-diabetic patients with SR showed a signifi cant improvement in 90-day death/shock/congestive heart failure compared with those without SR: 4.4% vs. 8.9% (p = 0.001). However, the composite outcome in diabetic patients did not reach statistical signifi cance: -10.0% with SR vs. 14.9% without (p = 0.270). Although they observed a trend towards improved 90-day mortality in non-diabetic patients with or without SR (2.2% vs. 3.6%, p = 0.1), no mortality benefi t was evident in diabetic patients with or without SR (4.3% vs. 6.1%, p = 0.79). Notably, when they examined outcomes according to tertiles of baseline blood glucose, both non-diabetic and diabetic patients with normoglycemia showed higher SR rates (15.5%, 10.3%, and 7.3% for non-diabetic patients, p < 0.001; 17.4%, 7.2%, and 9.1% for diabetic patients, p = 0.132) and improved 90-day death/shock/congestive heart failure (5.2%, 8.3%, and 14% for non-diabetic patients, p < 0.001; 8.7%, 4.2%, and 15.8% for diabetic patients, p = 0.006).
Limitations of the study
Our study has several limitations. TIMI fl ow in the IRA was assessed visually by the operator rather than by core laboratory analysis. We did not perform an analysis on the association between baseline glucose levels and the rate of SR. Because we analyzed patients with multivessel CAD, we do not know whether revascularization procedures during follow-up were elective (staged revascularization) or repeat revascularizations; therefore, we intentionally omitted this information in the results. Finally, these are observational data from one institution.
Conclusions
Diabetes mellitus is not an independent predictor of either pre-procedural or post-procedural TIMI 3 fl ow. When SR before intervention occurs, it is associated with a similar post-PCI improvement in epicardial blood fl ow both in diabetic and non--diabetic patients. SR improves in-hospital survival of diabetic patients, which is similar to the survival of non-diabetic patients without SR. The benefi cial effect of SR in diabetic patients disappears during 1-year follow-up.
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